Validated biomarkers could guide the development of IO agents in patients with HCC and CP B. The use of medical devices, such as tumor‐treating fields,103 as well as adoptive cell transfer, vaccination, and virotherapy represent possible new treatments to be studied in this patient population. Here, OPN1SW is linked to neoplasm.